

129th MAINE LEGISLATURE

FIRST REGULAR SESSION-2019

Legislative Document

No. 266

S.P. 78

In Senate, January 22, 2019

An Act To Eliminate the 2-year Limit on MaineCare Coverage for Approved Drugs for Opioid Use Disorder

Reference to the Committee on Health and Human Services suggested and ordered printed.

DAREK M. GRANT Secretary of the Senate

Presented by Senator SANBORN, L. of Cumberland. Cosponsored by Representative HYMANSON of York and

Senators: CLAXTON of Androscoggin, GRATWICK of Penobscot, MOORE of Washington,

Representative: PERRY of Calais.

1	Be it enacted by the People of the State of Maine as follows:
2	Sec. 1. 22 MRSA §3174-SS, as enacted by PL 2011, c. 477, Pt. I, §1, is repealed.
3 4	Sec. 2. 22 MRSA §3174-UU, sub-§7, ¶D, as amended by PL 2013, c. 368, Pt. AAAAA, §1, is further amended to read:
5 6 7 8	D. A MaineCare member for whom MaineCare reimbursement for opioid drugs for the treatment of addiction is restricted by limits applicable to methadone and a MaineCare member who is receiving buprenorphine and naloxone combination drugs for the treatment of addiction; and
9	SUMMARY
10 11 12	This bill repeals the 24-month limit on MaineCare coverage or reimbursement for buprenorphine and naloxone combination drugs, also known as Suboxone, for the treatment of addiction to opioids.